AgingResearch.NewsJoin free
American Journal of Obstetrics and Gynecology

Hormones linked to benefits in young advanced cervical cancer cohort

Among matched one-year survivors under 45 after chemoradiation for locally advanced cervical cancer, diabetes affected 5.3% of hormone users versus 9.8% of nonusers during long-term follow-up.

Paper by Ting-Fang Lu, Yu-Hsiang Shih, Yi Chen, +6 more authorsChien-Hsing Lu · Taichung Veterans General Hospital · National Chung Hsing University

Our read

Populations
Studied:
Cohort study of 4,656 women with locally advanced cervical cancer, against nonhormone therapy users (Multicenter)
What changed:
Type 2 diabetes was lower with hormone therapy: 5.3% versus 9.8% in nonhormone therapy users
The catch:
Hormone therapy duration and discontinuation could not be reliably measured
In the record:
The 413th paper on hormone replacement therapy with results in people; 985 on record in all. Its result on mortality agrees with 14 of 18 other findings on record; 1 points the other way and 3 found no change.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper
Follow @agingbrief

Women under 45 with locally advanced cervical cancer treated with chemotherapy and radiation together formed a matched observational cohort of 4,656 patients. All had survived one year after starting cancer treatment without a primary study outcome. Half began estrogen-based hormone therapy during that year; half did not. Median follow-up was 11.8 and 11.0 years, respectively.

Hormone use was associated with lower rates of type 2 diabetes: 5.3% versus 9.8%. Events affecting blood vessels in the brain occurred in 5.1% versus 8.9%, and compression fractures in 3.1% versus 7.4%. Hormone use was also linked to a lower rate of death over time. There were no statistically significant differences in blood clots, breast cancer or colorectal cancer.

Why it matters

Chemotherapy and radiation for cervical cancer can cause premature menopause, with lasting metabolic, bone and cardiovascular problems. The findings inform hormone-use decisions for women under 45 with locally advanced cervical cancer after these combined treatments.

Caveats

Women prescribed hormones may have differed in health or care in ways matching did not capture. The results concern women under 45 who survived the first year without a primary study outcome; hormone duration and discontinuation could not be reliably measured.

Comments

Be the first to comment.

More on Hormone replacement therapy